Vaccine prevention of rotavirus infection: Social significance and effectiveness
https://doi.org/10.22625/2072-6732-2017-9-2-65-71
Abstract
The rotavirus is the leading etiologic factor of intestinal infections. Epidemiological studies confirm the high prevalence of rotavirus gastroenteritis in children up to 5 years. WHO recommends the inclusion of routine vaccination against rotavirus infection in the national immunization programs of all countries with 2009. The article presents the experience and results of the introduction of vaccination against tear among children on the territory of Achinsk in Krasnoyarsk region.
Objective: to evaluate the effectiveness of the regional program of immunization of children on the territory of Achinsk in Krasnoyarsk region, with pentavalent rotavirus vaccine (PVRVV) (Merck, Sharp & Dohme Corp., USA, LP- 001865 dated 10/01/2012).
Methods.1267 children were immunized with PVRVV (80,0% of the newborn cohort) in the period July 2015 – June 2016: V1 – 1267; V2 – 918; V3 – 815. The vaccine was introduced, both independently and simultaneously with other vaccines of the Russian National Immunization Calendar (NIC), except for BCG (BCG-m). The immunization effect was evaluated in 2016 compared to 2014 (doubtingly period): reduction of IIs hospitalizations among 0-3 years old cohort, and reduction of IIs outpatient visits among pediatric and adult patients.
Results. Demonstrated safety and good tolerability of PVRVV, the overall rate of adverse events constituted 6,4±0,7, the possibility of combination with other vaccines of the NIC, no side effects with self-administration, reduction of IIs hospitalizations in 0–12 months years old group of vaccinated by 39,1%; among children not subject to vaccination (12–36 months) by 26,5%; the reduction of IIs outpatient visits both among pediatric and adult population.
Conclusion. Our study confirms numerous global observations of the fact that the RVI vaccination is one of the best ways to control the RVI incidence rate, thereby improving the socio-economic population well-being through preservation of life and health in children.
About the Authors
A. G. Yuzhakova
Krasnoyarsk State Medical University
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
G. P. Martynova
Krasnoyarsk State Medical University
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
References
1. Baranov A.A., Namazova-Baranova L.S. Federal clinical guidelines for the vaccine prophylaxis of rotavirus infection in children, 2015 (Ministry of Health of the Russian Federation, the Union of Pediatricians of Russia). – P. 7.
2. Briko N.I., Gorelov A.V. Rotavirus: contemporary view on the problem // Medical Bulletin. – 2013. – № 14-15. – P. 663-664.
3. Podkolzin A.T., Veselova O.A., Yakovenko M.L., Konovalova T.A., Petukhov D.N., Yatsyshina S.B., Vorobyova N.S., Shipulin G.A. Analysis of the structure of deaths among young children at acute intestinal infections // Infectious Diseases. – 2013. – № 2. – P. 38-44.
4. Yu J., Jung K., Kan H. Comparative Study between Febrile Convulsions and Benign Convulsions Associated with Viral Gastroenteritis // Journal of Epilepsy Research. – 2011. – Vol. 1, №. 1. – Р. 19-26.
5. Poslova L. Yu. Kovalishena O.V. Chubukona O.A. Sergeeva A.V. Clinical and epidemiological characteristics of rotaviral infection in children multipurpose day-and-night clinic // Medical Almanac. 2015. – Vol. 40, № 5. – Р. 60-65
6. Zlamy M., Kofler S., Orth D., Wurzner R., HeinzErian P., Streng A., Prelog M. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections // BMC Infectious Diseases. – 2013. – Vol. 13. – Р. 112.
7. Lanata C.F., Fischer-Walker C.L., Olascoaga A.C., Torres C.X., Aryee M. J., Black R. E. Global Causes of Diarrheal Disease Mortality in Children<5 Years of Age: A Systematic Review // PLOS ONE. – 2013. – Vol. 8, №. 9, – Р. 1-11.
8. WHO Ending Preventable Child Deaths from Pneumonia and Diarrhoea by 2025. The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD) [Electronic Resource] / WHO, 2013. – URL: http://apps.who.int/iris/bitstream/10665/79200/1/9789241505239_eng.pdf
9. WHO/IVB Database, as of 11 January 2016 Map production Immunization Vaccines and Biologicals (IVB), World Health Organization. [Electronic Resource] URL: http://www.who.int/immunization/monitoring_surveillance/VaccineIntroStatus.pptx
10. Dennehy P.H., Vesikari T., Matson D.O., Itzler R.F., Dallas M.J., Goveia M.G., DiNubile M.J., Heaton P.M., Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen) // Hum. Vaccin. – 2011. – Vol. 7 №. 5. – Р. 563-568.
11. Wang F.T., Mast T.C., Glass R.J., Seeger J.D. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States // The Pediatric Infectious Disease Journal. – 2012. – Vol. 32, №. 3
12. Baranov A.A. Children’s Diseases: Textbook / Moscow: GEOTAR-MED, 2-nd ed. – 2009. – 1008 с.
13. Martynova G.P., Yuzhakova A.G., Solovieva I.A. Rotavirus infection in children of Krasnoyarsk region: fist steps to reduce the incidence // Pharmateca. – 2016. № 11. – Р. 1-6.
14. Loughlin J., Mast T.C., Doherty M.C., Wang F.T., Wong J., Seeger J.D. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine // Pediatr. Infect. Dis. J. – 2012. – Vol. 31, № 3. – Р. 292-296.
15. WHO Weekly epidemiological record. – 2011. – Vol. 86, №. 30. – Р. 317–324.
Review
For citations:
Yuzhakova A.G., Martynova G.P. Vaccine prevention of rotavirus infection: Social significance and effectiveness. Journal Infectology. 2017;9(2):65-71. (In Russ.) https://doi.org/10.22625/2072-6732-2017-9-2-65-71
Views:
1305
.png)
.png)
Email this article 